Clinical Trial Update: PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating PD-1 antibody-based therapy with concurrent radiation therapy for early-stage natural killer/T-cell lymphoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Natural Killer T-cell Lymphoma

Drugs mentioned

• PD-1 antibody-based therapy

Snippet

Sponsor: Ruijin Hospital | Conditions: Natural Killer/T-cell Lymphoma | Phase 2 | Status: RECRUITING